ALBUQUERQUE, N.M. –Agilvax, Inc., a biotechnology company developing novel cancer immunotherapies and vaccines, announced today that it is now a resident company at Johnson & Johnson Innovation, JLABS (JLABS @ TMC) at the renowned Texas Medical Center—the world’s largest cancer center—located in Houston, TX .

Agilvax will utilize JLABS @ TMC facilities to support the development of the company’s lead cancer immunotherapy candidate, AX09, for the treatment of triple-negative breast cancer, as well as additional pipeline programs

Agilvax’s CEO, Dr. Federica Pericle stated, “We are honored and excited to be a resident company at JLABS @ TMC and join the growing biotechnology hub in Houston. Agilvax’s novel immunotherapy technology is a great fit for the Houston ecosystem where ground-breaking cancer research is occurring.”

JLABS @ TMC is a 34,000 square-foot life science innovation center, located in Houston, Texas. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a “no strings attached” model, Johnson & Johnson Innovation (JJI) does not take an equity stake in the companies occupying JLABS and the companies are free to develop products – either on their own, or by initiating a separate external partnership with JJI or any other company.